TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8934373
Drug: Lacidipine (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (2-6 mg)
Study: 1527233
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg orally followed by adinazolam 30 mg 1 hour later (treatment A)
Study: 1527233
Drug: Adinazolam alone
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam alone (treatment B)
Study: 4014629
Drug: Intravenous meptazinol
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meptazinol 2 mg/kg
Study: 17657327
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy (TH)
Study: 29081977
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no statin therapy)
Study: 22072154
Drug: Entecavir therapy
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir therapy (4 doses)
Study: 18460701
Drug: Candesartan cilexitil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexitil 16 mg
Study: 8701872
Drug: Probucol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (0.5 mg/day) administered between >7 days before PTCA and 3 months after PTCA
Study: 8701872
Drug: Probucol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (0.5 mg/day)
Study: 1341324
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by chemotherapy and selective radiotherapy to the brain for stage pT1-3N0M0 patients.
Study: 1341324
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by chemotherapy for stage pT1-3N2M0 patients.
Study: 1341324
Drug: Initial surgery
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial surgery for resectable tumors followed by postoperative chemotherapy.
Study: 1341324
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy followed by adjuvant surgery.
Study: 29294732
Drug: Group Cognitive-Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive-Behavioral Therapy (GCBT)
Study: 30025255
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) and GCBT
Study: 11518201
Drug: Margarine enriched
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine enriched with 1.5 g/d plant sterols
Study: 11518201
Drug: Margarine enriched
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine enriched with 3.0 g/d plant sterols
Study: 7687364
Drug: DSG low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSG low dose
Study: 7687364
Drug: DSG high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSG high dose
Study: 24504100
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg IV every 3 months for 24 months)
Study: 20071999
Drug: Vicriviroc 5
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 5 mg once daily
Study: 20071999
Drug: Vicriviroc 10
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 10 mg once daily
Study: 20071999
Drug: Vicriviroc 15
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 15 mg once daily
Study: 20672447
Drug: Vicriviroc (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc (all doses)
Study: 23415311
Drug: Lurasidone 80
Normalized name: lurasidone 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 80 mg
Study: 7823546
Drug: 4-hour hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hour hydration treatment
Study: 7823546
Drug: 4-hour dehydration
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-hour dehydration treatment
Study: 7823546
Drug: 4-hour placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hour placebo (control) treatment
Study: 28593789
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors
Study: 31182528
Drug: GSK3036656 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3036656 single doses of 5 mg (fed and fasted), 15 mg, and 25 mg; placebo as control
Study: 31182528
Drug: GSK3036656 repeat
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3036656 repeat doses of 5 mg and 15 mg; placebo as control
Study: 31182528
Drug: GSK3036656 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3036656 (both single and multiple doses)
Study: 27424014
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin (Group A)
Study: 27424014
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem (Group B)
Study: 27424014
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Group C)
Study: 23359967
Drug: ATRA combined
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA combined with Compound Huangdai Tablet
Study: 20028919
Drug: Interferon (intermediate-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (intermediate- versus low-dose)
Study: 11953279
Drug: Inhalative mucolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalative mucolytic drug mercapto‐ethane sulfonate (Mesna)
Study: 8669222
Drug: Mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.15 mg/kg (group A)
Study: 8669222
Drug: Mivacurium 0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.17 mg/kg (group B)
Study: 8669222
Drug: Mivacurium 0.19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.19 mg/kg (group C)
Study: 31511080
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with ambrisentan 10 mg plus tadalafil 40 mg
Study: 31511080
Drug: Pooled monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled monotherapy (ambrisentan 10 mg plus placebo or tadalafil 40 mg plus placebo)
Study: 18759737
Drug: Tertiary individual
Normalized name: Prednisolone tertiary butylacetate
DrugBank: Prednisolone tebutate (DB14632)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tertiary individual prevention (TIP) - 3 weeks inpatient treatment including intensive health care instruction and psychological counseling, followed by outpatient treatment by the local dermatologist.
Study: 24037015
Drug: Oral Appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Appliance
Study: 15060873
Drug: Ketodiet (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketodiet (0.3 g/kg/d protein plus tablets of KAs)
Study: 15060873
Drug: Placebo (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.6 g/kg/d protein plus placebo)
Study: 11552770
Drug: Reboxetine add
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine add on to haloperidol 5 mg
Study: 11552770
Drug: Placebo add
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo add on to haloperidol 5 mg
Study: 3125882
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg aspirin daily
Study: 28242866
Drug: Mitiglinide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiglinide (10 mg) and Voglibose (0.2 mg) (M+V) 3 times daily
Study: 28242866
Drug: Dipeptidyl Peptidase-4
Normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dipeptidyl Peptidase-4 Inhibitor (Linagliptin 5 mg) (L) once daily
Study: 28242866
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (M+V and L)
Study: 18974657
Drug: Antibiotic ointment
Normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic ointment (AO) prophylaxis
Study: 18974657
Drug: Catheter antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter antimicrobial locking (AL) with heparin + gentamicin (5.2 mg/ml)
Study: 12915429
Drug: Standard-dose guggulipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose guggulipid (1000 mg)
Study: 12915429
Drug: High-dose guggulipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose guggulipid (2000 mg)
Study: 12915429
Drug: Guggulipid (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guggulipid (both doses)
Study: 1539474
Drug: Thiopentone 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 4.5 mg.kg‐1
Study: 3886394
Drug: Binedaline 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binedaline 100 mg (females) and 150 mg (males)
Study: 3886394
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg and 75 mg
Study: 24698126
Drug: Local heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local heat therapy
Study: 29457317
Drug: Alcohol infusion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol infusion (0.08% blood alcohol level)
Study: 27416664
Drug: Dapoxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 30 mg qd
Study: 27416664
Drug: Control (Tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Tamsulosin 20 mg qd)
Study: 23606682
Drug: COBRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA therapy (prednisolone 60 mg/day, tapered to 7.5 mg/day in 6 weeks, methotrexate 7.5 mg/week, sulfasalazine 2 g/day)
Study: 23606682
Drug: COBRA-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-light therapy (lower dose prednisolone starting at 30 mg/day, tapered to 7.5 mg/day in 9 weeks, methotrexate escalated to 25 mg/week in 9 weeks)
Study: 16049639
Drug: Alanyl-glutamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl-glutamine (0.5 g x kg(‐1) x day(‐1) of undiluted alanyl‐glutamine (20%))
Study: 7728369
Drug: Biperiden (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (4 mg/day)
Study: 1674835
Drug: Active TENS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TENS during treatment and active TENS during stress
Study: 1674835
Drug: Active TENS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TENS during treatment and placebo TENS during stress
Study: 1674835
Drug: Placebo TENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TENS during treatment and placebo TENS during stress
Study: 1674835
Drug: Placebo TENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TENS during treatment and active TENS during stress
Study: 1674835
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment during both treatment and stress
Study: 6110504
Drug: Indenolol 40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indenolol 40, 80, 160, and 320 mg
Study: 6110504
Drug: Propranolol 40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40, 80, 160, and 320 mg
Study: 6734921
Drug: Buflomedil 600
Normalized name: buflomedil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 600 mg/day orally
Study: 27555505
Drug: Higher weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Higher weekly alcohol consumption
Study: 27555505
Drug: Diuretic use
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic use in participants with chronic kidney disease
Study: 18707117
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of collagen hydrolysate (CH) in 100 mL of fermented milk product (FMP)
Study: 18707117
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of collagen hydrolysate (CH) dissolved in 100 mL of water (neat hydrolyzed collagen)
Study: 11570641
Drug: Anti-IL-6 monoclonal
Normalized name: HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY (PF-04236921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-6 monoclonal antibody (1 microg/ml)
Study: 11570641
Drug: Anti-IL-10 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IL-10 monoclonal antibody (1 microg/ml)
Study: 11570641
Drug: Combined anti-IL-6
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anti-IL-6 and anti-IL-10 monoclonal antibodies (each at 1 microg/ml)
Study: 24565750
Drug: 0.15mmol/kg contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15mmol/kg contrast agent
Study: 20798988
Drug: Nurse-administered education
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered education program (Group 1)
Study: 20798988
Drug: Nurse-administered education
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered education program with additional pharmacist counseling (Group 2)
Study: 9585279
Drug: Epinephrine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.2 mg)
Study: 9585279
Drug: Bupivacaine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (7.5 mg) without epinephrine
Study: 30903614
Drug: Monthly household
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly household income
Study: 9170825
Drug: Dinoprostone vaginal
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal tablets
Study: 22057947
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (600 IU eCG on Day 4 after CIDR insertion)
Study: 22057947
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (300 IU eCG at the same time)
Study: 22057947
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (250 IU FSH on Day 4 post-insertion)
Study: 19155993
Drug: Aciclovir 400
Normalized name: Aciclovir 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 400 mg twice daily for 3 months
Study: 15744902
Drug: Panax notoginseng
Normalized name: PANAX NOTOGINSENG TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax notoginseng (PNG) 1,350 mg per day for 30 days
Study: 15744902
Drug: Starch capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch capsule (control) 1,350 mg per day for 30 days
Study: 16305977
Drug: valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 160 mg/day
Study: 11991217
Drug: captopril 100
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 100 mg/day
Study: 11991217
Drug: combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined therapy (valsartan + captopril)
Study: 7539853
Drug: Doxazosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (8 mg once daily)
Study: 2181787
Drug: Telenzepine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine (3 mg in the morning)
Study: 382150
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg t.d.s.)
Study: 339141
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg water-soluble bioflavonoids and 600 mg ascorbic acid, administered three times daily
Study: 339141
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg water-soluble bioflavonoids and 1000 mg ascorbic acid, administered five times daily
Study: 26620248
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once a day
Study: 30601059
Drug: Positive Strategies
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Strategies To Enhance Problem‐solving Skills (Positive STEPS) intervention, which includes five individual counseling sessions and daily text message reminders.
Study: 19769016
Drug: Contemplative/preparation group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contemplative/preparation group
Study: 11498062
Drug: 0.12% zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% zinc sulfate nasal spray administered as two inhalations in each nostril four times a day
Study: 11498062
Drug: Isotonic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic placebo spray
Study: 4016543
Drug: Augmentin (1.2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin (1.2g intravenously pre-operatively, with 8 additional doses for gangrenous or perforated appendices)
Study: 4016543
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg intravenously pre-operatively, with 8 additional doses for gangrenous or perforated appendices)
Study: 30058572
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus chemotherapy (R-chemo)
Study: 26233481
Drug: Aclidinium/formoterol 400/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium/formoterol 400/12 μg
Study: 25404569
Drug: Aclidinium/formoterol 400/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium/formoterol 400/6 μg
Study: 23091141
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation of 2.5 g/kg LFA
Study: 23091141
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation of 5.0 g/kg LFA
Study: 2104735
Drug: Inhaled ergotamine
Normalized name: ergotamine tartrate Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ergotamine tartrate (1 puff, 0.36 mg)
Study: 1324238
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg/day
Study: 8647515
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg/day
Study: 28603868
Drug: Postoperative block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative block with 0.5 ml.kg‐1 ropivacaine 0.75%
Study: 26014587
Drug: Transdermal donepezil
Normalized name: donepezil Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal donepezil patch 87.5 mg/25 cm(2) every 72 h
Study: 26014587
Drug: Transdermal donepezil
Normalized name: donepezil Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal donepezil patch 175 mg/50 cm(2) every 72 h
Study: 21716277
Drug: LBM415 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBM415 at 1,000 mg b.i.d.
Study: 21716277
Drug: LBM415 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBM415 at 1,000 mg t.i.d.
Study: 21716277
Drug: LBM415 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBM415 at low doses (not specified)
Study: 21716277
Drug: LBM415 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBM415 at 1,000 mg single dose
Study: 15296889
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 1.5 g as a bolus, followed by a constant infusion of 200 mg/h until 1.5 g
Study: 28303632
Drug: UFH monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH monotherapy
Study: 16684823
Drug: Metformin (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (425 mg/d) for 2 years
Study: 15277255
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 i.v. followed by paclitaxel 150 mg/m2 i.v. over 24 h plus filgrastim 5 microg/kg on days 3-12 (arm 2)
Study: 15277255
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 i.v. followed by cisplatin 50 mg/m2 i.v. (arm 1)
Study: 11351769
Drug: Formoterol via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol via Aerolizer inhaler (12 micrograms twice daily)
Study: 11351769
Drug: Formoterol via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol via Turbuhaler inhaler (12 micrograms twice daily)
Study: 9236262
Drug: Ipriflavone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (200 mg t.i.d.)
Study: 3092363
Drug: Triaging patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triaging patients into various combinations of health education treatments
Study: 29795295
Drug: 0.1% GRFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% GRFT gel (HEC formulation)
Study: 29795295
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (HEC formulation)
Study: 27180881
Drug: Arnebia euchroma
Normalized name: ARNEBIA EUCHROMA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnebia euchroma ointment (AEO)
Study: 25730540
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream (SSD)
Study: 21455255
Drug: DOCp53 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOCp53 group (trans-tracheal Adp53 injection at 1 × 10(12) vp on day 1 and day 8, plus docetaxel at 75 mg/m² on day 2)